Availability of hepatitis C diagnostics and therapeutics in
European and Eurasia countries

J 2018

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

LEBLEBICIOGLU, Hakan, Joop E. ARENDS, Resat OZARAS, Giampaolo CORTI, Lurdes SANTOS et. al.

Basic information

Original name

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Authors

LEBLEBICIOGLU, Hakan (792 Turkey, guarantor), Joop E. ARENDS (528 Netherlands), Resat OZARAS (792 Turkey), Giampaolo CORTI (380 Italy), Lurdes SANTOS (620 Portugal), Christoph BOESECKE (276 Germany), Andrew USTIANOWSKI (826 United Kingdom of Great Britain and Northern Ireland), Ann Sofi DUBERG (752 Sweden), Simona RUTA (642 Romania), Nermin N. SALKIC (70 Bosnia and Herzegovina), Petr HUSA (203 Czech Republic, belonging to the institution), Ivana LAZAREVIC (688 Serbia), Juan A. PINEDE (724 Spain), Natalia Y. PSHENICHNAYA (643 Russian Federation), Tengiz TSERTSWADZE (268 Georgia), Mojca MATICIC (705 Slovenia), Edmond PUCA (8 Albania), Gulzhan ABUOVA (398 Kazakhstan), Judit GERVAIN (348 Hungary), Ramin BAYRAMLI (31 Azerbaijan), Salih AHMETI (95 Republic of Kosovo), Mairi KOULENTAKI (300 Greece), Badreddine KILANI (788 Tunisia), Adriana VINCE (191 Croatia), Francesco NEGRO (756 Switzerland), Mustafa SUNBUL (792 Turkey) and Domonique SALMON (250 France)

Edition

ANTIVIRAL RESEARCH, AMSTERDAM, ELSEVIER SCIENCE BV, 2018, 0166-3542

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30303 Infectious Diseases

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 4.130

RIV identification code

RIV/00216224:14110/18:00102717

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.antiviral.2017.12.001

UT WoS

000425078700002

Keywords in English

Availability of hepatitis C diagnostics; Therapeutics in European and Eurasia countries

Abstract

V originále

Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. Methods: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. Results: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (<= 1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. Conclusion: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.

Citovat

LEBLEBICIOGLU, Hakan, Joop E. ARENDS, Resat OZARAS, Giampaolo CORTI, Lurdes SANTOS, Christoph BOESECKE, Andrew USTIANOWSKI, Ann Sofi DUBERG, Simona RUTA, Nermin N. SALKIC, Petr HUSA, Ivana LAZAREVIC, Juan A. PINEDE, Natalia Y. PSHENICHNAYA, Tengiz TSERTSWADZE, Mojca MATICIC, Edmond PUCA, Gulzhan ABUOVA, Judit GERVAIN, Ramin BAYRAMLI, Salih AHMETI, Mairi KOULENTAKI, Badreddine KILANI, Adriana VINCE, Francesco NEGRO, Mustafa SUNBUL and Domonique SALMON. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. ANTIVIRAL RESEARCH. AMSTERDAM: ELSEVIER SCIENCE BV, 2018, vol. 150, FEB 2018, p. 9-14. ISSN 0166-3542. Available from: https://dx.doi.org/10.1016/j.antiviral.2017.12.001.

@article{1417176,
   author = {Leblebicioglu, Hakan and Arends, Joop E. and Ozaras, Resat and Corti, Giampaolo and Santos, Lurdes and Boesecke, Christoph and Ustianowski, Andrew and Duberg, Ann Sofi and Ruta, Simona and Salkic, Nermin N. and Husa, Petr and Lazarevic, Ivana and Pinede, Juan A. and Pshenichnaya, Natalia Y. and Tsertswadze, Tengiz and Maticic, Mojca and Puca, Edmond and Abuova, Gulzhan and Gervain, Judit and Bayramli, Ramin and Ahmeti, Salih and Koulentaki, Mairi and Kilani, Badreddine and Vince, Adriana and Negro, Francesco and Sunbul, Mustafa and Salmon, Domonique},
   article_location = {AMSTERDAM},
   article_number = {FEB 2018},
   doi = {http://dx.doi.org/10.1016/j.antiviral.2017.12.001},
   keywords = {Availability of hepatitis C diagnostics; Therapeutics in European and Eurasia countries},
   language = {eng},
   issn = {0166-3542},
   journal = {ANTIVIRAL RESEARCH},
   title = {Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries},
   volume = {150},
   year = {2018}
}

TY  - JOUR
ID  - 1417176
AU  - Leblebicioglu, Hakan - Arends, Joop E. - Ozaras, Resat - Corti, Giampaolo - Santos, Lurdes - Boesecke, Christoph - Ustianowski, Andrew - Duberg, Ann Sofi - Ruta, Simona - Salkic, Nermin N. - Husa, Petr - Lazarevic, Ivana - Pinede, Juan A. - Pshenichnaya, Natalia Y. - Tsertswadze, Tengiz - Maticic, Mojca - Puca, Edmond - Abuova, Gulzhan - Gervain, Judit - Bayramli, Ramin - Ahmeti, Salih - Koulentaki, Mairi - Kilani, Badreddine - Vince, Adriana - Negro, Francesco - Sunbul, Mustafa - Salmon, Domonique
PY  - 2018
TI  - Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries
JF  - ANTIVIRAL RESEARCH
VL  - 150
IS  - FEB 2018
SP  - 9-14
EP  - 9-14
PB  - ELSEVIER SCIENCE BV
SN  - 01663542
KW  - Availability of hepatitis C diagnostics
KW  - Therapeutics in European and Eurasia countries
N2  - Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. Methods: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. Results: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (<= 1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. Conclusion: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.
ER  -

LEBLEBICIOGLU, Hakan, Joop E. ARENDS, Resat OZARAS, Giampaolo CORTI, Lurdes SANTOS, Christoph BOESECKE, Andrew USTIANOWSKI, Ann Sofi DUBERG, Simona RUTA, Nermin N. SALKIC, Petr HUSA, Ivana LAZAREVIC, Juan A. PINEDE, Natalia Y. PSHENICHNAYA, Tengiz TSERTSWADZE, Mojca MATICIC, Edmond PUCA, Gulzhan ABUOVA, Judit GERVAIN, Ramin BAYRAMLI, Salih AHMETI, Mairi KOULENTAKI, Badreddine KILANI, Adriana VINCE, Francesco NEGRO, Mustafa SUNBUL and Domonique SALMON. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. \textit{ANTIVIRAL RESEARCH}. AMSTERDAM: ELSEVIER SCIENCE BV, 2018, vol.~150, FEB 2018, p.~9-14. ISSN~0166-3542. Available from: https://dx.doi.org/10.1016/j.antiviral.2017.12.001.

Detailed Information on Publication Record